Alzheimer's Disease (AD) is the most common neurodegenerative disease worldwide. So, there is a need to identify AD early diagnosis and monitoring biomarkers in blood samples. The aim of this study was to analyse the utility of lipid peroxidation biomarkers in AD progression evaluation. Participants (n = 19) were diagnosed with AD at early stages (Time 0, T0), and they were re-evaluated 2 years later (Time 1, T1). Plasma biomarkers from AD patients were determined at both times. Some analytes, such as dihomo-isoprostanes (17-epi-17-F2t-dihomo-IsoP, 17-F2t-dihomo-IsoP, Ent-7(RS)-7-F2t-dihomo-IsoP), and neuroprostanes (10-epi-10-F4t-NeuroP) showed very high probability of showing an increasing trend over time. Baseline values allowed to develop an affordable preliminary regression model to predict long-term cognitive status. So, some lipid peroxidation biomarkers would deserve consideration as useful progression AD biomarkers. The developed prediction model would constitute an important minimally invasive approach in AD personalized prognosis and perhaps could have some interest also in experimental treatments evaluation.

中文翻译：

---

血浆异前列腺素评估作为阿尔茨海默病进展生物标志物

阿尔茨海默病 (AD) 是全球最常见的神经退行性疾病。因此，需要在血液样本中识别 AD 早期诊断和监测生物标志物。本研究的目的是分析脂质过氧化生物标志物在 AD 进展评估中的效用。参与者 ( n = 19）在早期（时间 0，T0）被诊断为 AD，并在 2 年后（时间 1，T1）重新评估。两次都确定了来自 AD 患者的血浆生物标志物。一些分析物，例如二高异前列腺素（17-epi-17-F2t-dihomo-IsoP、17-F2t-dihomo-IsoP、Ent-7(RS)-7-F2t-dihomo-IsoP）和神经前列腺素 (10- Epi-10-F4t-NeuroP) 显示出随时间增加趋势的可能性非常高。基线值允许开发负担得起的初步回归模型来预测长期认知状态。因此，一些脂质过氧化生物标志物值得考虑作为有用的进展 AD 生物标志物。开发的预测模型将构成 AD 个性化预后的重要微创方法，并且可能对实验治疗评估也有一些兴趣。